Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIT | P10721 | 4/20 | 0.76 |
| ▸ | JAK2 | O60674 | 3/20 | 0.60 |
| ▸ | JAK3 | P52333 | 3/20 | 0.60 |
| ▸ | PAK1 | Q13153 | 5/20 | 0.58 |
| ▸ | LCK | P06239 | 1/20 | 0.56 |
| ▸ | AKT2 | P31751 | 3/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.55 |
| ▸ | JAK1 | P23458 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29230342 | 0.87 | PAK1 (0.73) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL9967045 | 0.86 | KIT (0.65) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL15664203 | 0.86 | KIT (1.00) | KITPAK1LCKAKT2GSK3B | |
| SCHEMBL9967157 | 0.86 | JAK2 (0.65) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL15515055 | 0.86 | PAK1 (0.74) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL9967220 | 0.85 | JAK3 (0.58) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL9967160 | 0.83 | JAK3 (0.61) | KITJAK2JAK3PAK1LCK | |
| SCHEMBL15664101 | 0.82 | KIT (0.67) | KITJAK2JAK3LCKAKT2 | |
| SCHEMBL15664350 | 0.82 | KIT (0.69) | KITJAK2JAK3LCKAKT2 | |
| SCHEMBL15664156 | 0.81 | KIT (0.74) | KITJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892534-B1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC (US) | 2021-08-04 | — | — | EP | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | PLEXXIKON INC. (US) | 2019-03-12 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | PLEXXIKON INC. | 2014-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227357-B2 | Compounds and methods for kinase modulation, and indications therefor | KIT, PRKCH, PRKACA | KIT 1/4885JAK2 150/4885JAK3 148/4885 |
| US-20140128390-A1 | COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR | KIT, PRKCH, PRKACA | KIT 1/4885JAK2 150/4885JAK3 148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.